Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...
The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...
Indian River County recorded the highest rate of new cases on the Treasure Coast, with 14 per 100,000 people diagnosed with ...
Local political activists put their heads together after first case of infection confirmed in 18-month-old girl.
Delhi High Court has granted three weeks' parole to a convict in the 2009 murder of IT executive Jigisha Ghosh, allowing him ...
Stocktwits on MSN
Merck Says Its Two-Drug Regimen For HIV Treatment Proven Non-Inferior To Gilead’s Biktarvy In Study
The safety profile of the regimen was also found to be comparable to Biktarvy. ・Merck now intends to present findings from ...
The ECDC says the region could still meet its testing targets for HIV, but that it will be harder to improve detection for ...
The candlelighting ceremony at the World AIDS Day commemorative event. (Photo: PIA Samar) An early World AIDS Day observance ...
Gilead Sciences has announced positive topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of adults with HIV who ...
Women are disproportionately affected by HIV, making up nearly half of new infections globally and in India. Stigma, gender ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback